Skip to main content
Cyfuse Biomedical K.K. logo

Cyfuse Biomedical K.K. — Investor Relations & Filings

Ticker · 4892 ISIN · JP3311800001 T Manufacturing
Open in API
Filings indexed 36 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country JP Japan
Listing T 4892

About Cyfuse Biomedical K.K.

https://en.cyfusebio.com/

Cyfuse Biomedical K.K. is a research and development company specializing in regenerative medicine through its proprietary bio 3D printing platform technology. The company's core innovation is a scaffold-free method for fabricating three-dimensional tissues and organs by fusing cellular aggregates, known as spheroids. This approach allows for the creation of complex biological structures using cells exclusively. Cyfuse develops, manufactures, and commercializes its bio 3D printers, including the Regenova® and S-PIKE® systems. These technologies are aimed at advancing applications in drug discovery, preclinical research, and the development of cellular products for therapeutic tissue and organ regeneration.

Recent filings

Filing Released Lang Actions
譲渡制限付株式報酬としての新株式発行の払込完了に関するお知らせ
Regulatory Filings
2026-04-24 Japanese
新株予約権の取得及び消却並びに資金使途の変更に関する決定のお知らせ
Regulatory Filings
2026-04-15 Japanese
確認書
Regulatory Filings Classification · 70% confidence The document is a brief confirmation letter (確認書) filed under the Financial Instruments and Exchange Act to the Kanto Finance Bureau, attesting to the accuracy of the company’s FY16 Securities Report. It is not the Securities Report itself, nor any other specific report type (e.g., AGM materials, earnings release). This small regulatory submission falls into the general “Regulatory Filings” category.
2026-03-27 Japanese
有価証券報告書－第16期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains the official header, fiscal period (2025-01-01 to 2025-12-31), company information, financial highlights, and historical development details. It is a comprehensive annual financial report filed with the Kanto Local Finance Bureau. FY 2025
2026-03-27 Japanese
有価証券届出書（組込方式）
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kanto Local Finance Bureau by Cyfuse Biomedical K.K. It details a third-party allotment of shares (capital increase) to Kuraray Co., Ltd. This type of filing is a regulatory requirement for issuing new securities in Japan. Since it is a formal regulatory filing regarding capital changes and share issuance, it falls under the 'Share Issue/Capital Change' category.
2025-12-24 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically confirming the accuracy of the contents of a Semi-Annual Report (Hankishokokusho) for the period ending June 30, 2025. Since this is a regulatory filing required by law to accompany financial reports and does not fit into the specific categories of the reports themselves, it falls under the general regulatory filing category.
2025-08-14 Japanese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.